Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride replenishes potassium stores. Dextrose provides caloric support via glucose metabolism. Sodium chloride maintains osmotic balance and fluid volume.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion only; typical adult dose is 1 L at a rate of 100-200 mL/hour, delivering 0.22% KCl (2.2 g KCl = 29.9 mEq K+), 5% dextrose, and 0.11% NaCl (1.1 g NaCl = 18.8 mEq Na+, 18.8 mEq Cl-). Dose depends on potassium deficit and renal function.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium does not have a defined terminal half-life in the traditional sense, as it is tightly regulated. The elimination half-life of potassium ions from the plasma is approximately 1-1.5 hours for acute distribution, but the overall body turnover is much slower. In clinical context, after IV infusion, plasma concentration declines rapidly due to cellular uptake and renal excretion.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium is primarily excreted renally (about 90%) with the remainder eliminated via feces. In this formulation, the dextrose and sodium chloride are also excreted renally, with dextrose being fully reabsorbed when normoglycemic. Excretion data for potassium: renal ~90%, fecal ~10%.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."